Array BioPharma Inc. (NASDAQ:ARRY) Files An 8-K Results of Operations and Financial Condition
Item 2.02
Results of Operations and Financial Condition.
On February 5, 2019, Array BioPharma Inc. (the “Company”) issued a press release reporting results for the second quarter of fiscal year ending June 30, 2019, the full text of which is furnished hereto as Exhibit 99.1 and incorporated herein by reference. The information in Item 2.02 of this Form 8-K and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
On February 5, 2019, the Company posted on its website at www.arraybiopharma.com, under the “Investors” tab, a presentation on certain financial, operational and clinical program updates. A copy of the presentation, which will be available for viewing during today’s conference call, is furnished hereto as Exhibit 99.2 and incorporated herein by reference. The information in Item 2.02 of this Form 8-K and Exhibit 99.2 hereto shall not be deemed “filed” for purposes of Section18 of the Exchange Act or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
|
Item 2.02 |
Financial Statements and Exhibits. |
(d)Exhibits
ARRAY BIOPHARMA INC Exhibit
EX-99.1 2 ex991.htm EXHIBIT 99.1 ex991 News Release Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019 – Strong quarter for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. with $22.7 million in net product sales,…
To view the full exhibit click here
About Array BioPharma Inc. (NASDAQ:ARRY)
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.